Early and repeated use of plasma for the management of Ebola patients: Reflection around a case

• DOI: 10.1016/j.tracli.2016.08.005
• Publication Date: 2016-09-16T00:16:49Z
• Authors: F. Dufour-Gaume; D. Delaune; C. Martinaud; A. Sailliol
• Keywords: Male; Disease Management; Blood Component Transfusion; Hemorrhagic Fever, Ebola; Amides; Combined Modality Therapy; Severity of Illness Index; Anti-Bacterial Agents; 3. Good health; Plasma; Young Adult; 03 medical and health sciences; Freeze Drying; 0302 clinical medicine; Gastrointestinal Agents; Blood Preservation; Pyrazines; Humans

In December 2013, the most widespread epidemic of Ebola virus disease began in Guinea and continued for over 2 years. At the request of the Guinean state, France deployed a military field hospital to treat Ebola infected healthcare workers. From January to July 2015, our center supported 26 healthcare workers suffering from Ebola virus disease. Despite an individualized care and optimal treatment, the fatality rate remained high at 30.7%. Improved therapies are required to reduce mortality risk in Ebola virus disease. We report the case of a patient admitted to the hospital on the 4th day after onset, who survived despite several clinical and biological predictors of fatal outcome. We transfused plasma at a high dose and spread over time. This innovative therapeutic approach was based on our clinical experience of Ebola patients' management, literature review and knowledge of plasma ability to restore coagulation disorders and endotheliopathy. Even without any bleeding sign, coagulopathy and endothelial permeability disorders participate in hypovolemia and fatal multi-system organ failure. Early intake of therapeutic plasma at repeated doses seems to reduce the endothelial permeability and coagulation disorders related to Ebola virus disease.